研究领域

本课题组致力于解析T细胞在肿瘤中浸润、存活的微环境支持条件以及在免疫治疗条件下T细胞功能性衰竭的分子机制，并以此开发新型肿瘤免疫治疗策略、抗体药物和肿瘤疫苗。

成果

卢长征博士从2012年开始进入肿瘤免疫领域，博士阶段研究课题是与Seven& Eight Biopharma合作研发抗肿瘤免疫药物。所研药物已申请7项美国专利，先后在欧美开展I、II期临床试验，现已被默沙东前研发掌门人Roger M Perlmutter博士领导的Eikon Therapeutics收购。2016年加入美国西南医学中心进行博士后训练，研究课题之一发表在Cancer Cell 杂志（被欧洲癌症研究学会评为2020年度十大癌症研究论文），解析了DNA错配修复缺失型（dMMR）肿瘤响应和抵抗PD-1抗体治疗的机制，揭示了肿瘤细胞自身的cGAS-STING通路对于肿瘤微环境中T细胞浸润水平的调控作用，为精准免疫治疗提供了新的标志物。

荣誉

· 2021 国家级高层次人才工程（青年）

· 2020 欧洲癌症研究学会十大癌症研究进展论文

· 2009/2010 & 2013/2014 中国科学院研究生院三好学生

· 2009/2010 中国科学院研究生院优秀学生干部

招聘

1. 1. 副研究员/助理研究员（肿瘤免疫治疗）

2. 2. 博士后（肿瘤免疫治疗）

3. 3. 研究助理（肿瘤免疫治疗）
   

代表论文

1. Huang, Y.#, Lu, C.#, Wang, H., ... & Li, G. M. (2023). DNAJA2 deficiency activates cGAS-STING pathway via the induction of aberrant mitosis and chromosome instability. Nature Communications,14(1):5246.

2. Cai, Y., Zhang, A., Lu, C.*. (2022). Precision intervention of cell type-specific targeting is required for future cancer immunotherapy. Medical Review, 2(6), 553-554.

3. Lu, C.#, Guan, J.#, Lu, S., Jin, Q., Rousseau, B., Lu, T., ... & Fu, Y. X. (2021). DNA sensing in mismatch repair-deficient tumor cells is essential for anti-tumor immunity. Cancer Cell, 39(1), 96-108.

This paper is previewed by Cancer Cell (https://www.cell.com/cancer-cell/fulltext/S1535-6108(20)30664-4); Elected as EACR’s Top 10 Cancer Research Publications in 2020; A highly cited paper in Web of Science.

4. Guan, J.#, Lu, C.#, Jin, Q., Lu, H., Chen, X., Tian, L., ... & Li, G. M. (2021). MLH1 deficiency-triggered DNA hyperexcision by exonuclease 1 activates the cGAS-STING pathway. Cancer Cell, 39(1), 109-121. A highly cited paper in Web of Science.

5. Liu, L., Chen, J., Zhang, H., Ye, J., Moore, C., Lu, C., Fang, Y., Fu, Y. X., & Li, B. (2022). Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunity. Nature cancer, 3(4), 437–452.

6. Zhang, A., Ren, Z., Tseng, K. F., Liu, X., Li, H., Lu, C., Cai, Y., Minna, J. D., & Fu, Y. X. (2021). Dual targeting of CTLA-4 and CD47 on T_reg cells promotes immunity against solid tumors. Science translational medicine, 13(605), eabg8693. 

7. Li, H. D., Lu, C., Zhang, H., Hu, Q., Zhang, J., Cuevas, I. C., Sahoo, S. S., Aguilar, M., Maurais, E. G., Zhang, S., Wang, X., Akbay, E. A., Li, G. M., Li, B., Koduru, P., Ly, P., Fu, Y. X., & Castrillon, D. H. (2020). A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response. JCI insight, 5(14), e138829. 

8. Han, C., Liu, Z., Zhang, Y., Shen, A., Dong, C., Zhang, A., Moore, C., Ren, Z., Lu, C., Cao, X., Zhang, C. L., Qiao, J., & Fu, Y. X. (2020). Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling. Nature immunology, 21(5), 546–554. 

9. Suresh, S., Chen, B., Zhu, J., Golden, R. J., Lu, C., Evers, B. M., Novaresi, N., Smith, B., Zhan, X., Schmid, V., Jun, S., Karacz, C. M., Peyton, M., Zhong, L., Wen, Z., Sathe, A. A., Xing, C., Behrens, C., Wistuba, I. I., Xiao, G., … O'Donnell, K. A. (2020). eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer. Nature cancer, 1(5), 533–545. 

10. Liu, Z., Han, C., Dong, C., Shen, A., Hsu, E., Ren, Z., Lu, C., Liu, L., Zhang, A., Timmerman, C., Pu, Y., Wang, Y., Chen, M., Qiao, J., & Fu, Y. X. (2019). Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity. Science immunology, 4(38), eaav6473. 

11. Li, H. D., Cuevas, I., Zhang, M., Lu, C., Alam, M. M., Fu, Y. X., You, M. J., Akbay, E. A., Zhang, H., & Castrillon, D. H. (2018). Polymerase-mediated ultramutagenesis in mice produces diverse cancers with high mutational load. The Journal of clinical investigation, 128(9), 4179–4191.